➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Mallinckrodt
Dow
McKesson
Boehringer Ingelheim

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,179,216

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,179,216 protect, and when does it expire?

Patent 10,179,216 protects XHANCE and is included in one NDA.

This patent has fifteen patent family members in twelve countries.

Summary for Patent: 10,179,216
Title:Nasal delivery devices
Abstract: A nasal delivery device comprising: a housing (15); a nosepiece (17) for fitting to a nasal cavity of a subject; a mouthpiece (19) through which the subject in use exhales; and a substance supply unit (21) including an actuation member (23) which extends from one end of the housing and is manually actuated to deliver substance to the nasal cavity of the subject; wherein the housing includes a grip section (27) which is disposed at the one end of the housing from which the actuation member extends, said grip section comprising a first, distal part (28) including at least one projecting grip element (29) by which the subject grips the housing in actuating the actuation member, and a second, proximal part (31) providing a recess (33) in which fingers of the subject are located, said recess promoting proper orientation of the delivery device in a hand of the subject.
Inventor(s): Djupesland; Per Gisle (Oslo, NO), Dudgeon; Kate (Providence, RI), Gordon; Joseph (Mansfield, MA), Guarraia; Mark (Cranston, RI), Leclerc; Michael (Cranston, RI), Mahmoud; Ramy A (Skillman, NJ)
Assignee: OptiNose AS (Oslo, NO)
Application Number:14/380,836
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;

Drugs Protected by US Patent 10,179,216

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes   Start Trial   Start Trial Y METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,179,216

PCT Information
PCT FiledFebruary 25, 2013PCT Application Number:PCT/EP2013/053748
PCT Publication Date:August 29, 2013PCT Publication Number: WO2013/124493

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
AstraZeneca
McKinsey
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.